Up Close with Epcoritamab
Last Updated: January 15, 2026
Discover more about epcoritamab-bysp (EPKINLY®).
Related Resources:
PQI in Action
PQI in Action: Epcoritamab (Epkinly) for Relapsed/Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma
Last Updated: 10/09/2025
PQI
PQI: Epcoritamab (Epkinly) for Relapsed/Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma
Last Updated: 05/05/2026
Perspectives
OncolyticsToday: The Bispecific Antibody Revolution
Author: KELLY BRUNK
Last Updated: 04/01/2024
Find Similar Resources:
Immunotherapy
Immunotherapy
Immunotherapy
Immunotherapy
Up Close with Linvoseltamab
Last Updated: 06/29/2026
Overview of BTCEs: Comparison of Bispecific T-Cell Engagers (BTCEs)
Last Updated: 04/23/2026
Example SOPs and Documents: Transitioning Patients on Bispecific T-Cell Engagers Between Care Settings
Last Updated: 07/01/2025
Example SOPs and Documents: Bispecific T-cell Engager Billing Procedure
Last Updated: 07/01/2025
PQI in Action
Patient Education Sheet
Patient Education Sheet
PQI in Action: Revumenib (Revuforj) for the Management of Acute Leukemia
Last Updated: 06/30/2026
Acalabrutinib, Venetoclax, and Obinutuzumab
Last Updated: 06/29/2026
Afamitresgene Autoleucel
Last Updated: 06/29/2026
Step Edit Series
Last Updated: 07/02/2026